Background. Patients with moderate-to-severe psoriasis are often treated with systemic immunosuppressant agents that decrease\r\nimmune system function. For the elderly, these medications are often problematic due to their already immunosuppressed state\r\nand comorbidities. However, there are few studies examining the effects of these medications on the elderly age group. Therefore,\r\nthere is often discomfort among dermatologists treating elderly patients with psoriasis in utilizing systemic agents, frequently\r\nresulting in inadequate treatment. Objective. We review the safety profiles of systemic treatments often used to treat psoriasis\r\nand their possible adverse risks to the geriatric population. Methods. We conducted a search of PubMed�s Medline database of\r\narticles published from 2000 to 2011, which resulted in 14 articles. Conclusion. Treating geriatric patients with moderate-to-severe\r\npsoriasis remains a challenge due to immunosenescence and comorbidities.More studies focusing on psoriasis treatment safety in\r\nthe geriatric population are needed.
Loading....